Volpara (ASX:VHT) share price edges lower despite biggest contract win

It seems the medical imaging company's shares are being dragged lower by broader market weakness.

| More on:
a sonographer monitors an image of a patient's breast on a screen with the patient standing at an imaging device in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is heading south today regardless of the company's significant positive announcement.

At the time of writing, the healthcare technology company's shares are down 2.54% to $1.15.

Volpara secures largest-ever contract

According to the company's announcement, Volpara advised it has signed its biggest contract to date with a leading US outpatient diagnostic imaging provider.

The five-year deal is valued at US$2.15 million which represents an annual recurring revenue (ARR) of US$430,000.

Under the agreement, Volpara will install its Patient Hub software across the customer's network of imaging centres. The software solution is expected to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard.

As such, this will enable the customer to accurately decide the appropriate personalised breast cancer screening pathway for each patient.

Volpara estimates that at least one of its software products is used in the breast cancer screening of more than 33% of women in the US.

Whilst the announcement is extremely positive, it appears the broader All Ordinaries Index (ASX: XAO) is weighing down the Volpara share price. The index is currently down 0.90% to 7,508.7 points.

Volpara group CEO Dr Ralph Highnam commented:

While we would not normally announce individual deals, this is Volpara's highest-value contract signed to date.

We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve.

Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago.

About the Volpara share price

The past 12 months have been disappointing for investors with the company's shares down 13%. Year-to-date, their losses are further magnified, almost 20% lower over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $29 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »